The filing of a mixed-securities shelf by Theriva Biologics indicates the company's preparation for future capital raising activities. This could be viewed positively by investors as it provides the company with the flexibility to fund operations and research and development projects, potentially leading to growth and value creation. However, the impact on the stock price will depend on the market's perception of the company's growth prospects and how effectively it uses the raised capital.